home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Pharma Pricing & Market Access Europe 2012

 
  January 25, 2012  
     
 
Health Network Communications, London
2012/02/20


8am Registration and coffee
8.45am Opening remarks from the chair
Ed SchoonveldEd Schoonveld is a Principal with ZS Associates in Princeton, NJ and Lead for the firm’s Market Access and Pricing Practice. He has extensive experience in pharmaceutical marketing and pricing from both the corporate pharma and consultancy...
more..
› Ed Schoonveld, Principal, Market Access & Pricing Lead and Author of ""The Price of Global Health"", ZS Associates
 
 
9am Overview of current issues and trends in global market access and pricing
Ed SchoonveldEd Schoonveld is a Principal with ZS Associates in Princeton, NJ and Lead for the firm’s Market Access and Pricing Practice. He has extensive experience in pharmaceutical marketing and pricing from both the corporate pharma and consultancy...
more..
•Price controls: is the cure worse than the condition?
•Overview of current developments in MA&P
•Where are UK and Germany heading?
•Impact on drug company strategies

› Ed Schoonveld, Principal, Market Access & Pricing Lead and Author of ""The Price of Global Health"", ZS Associates
 
 
9.25am Modernising healthcare: The path ahead
 
•How can industry contribute to provide evidence that decision-makers require - throughout the life-cycle?
•How can payers and HTA bodies stimulate the development of new medicines that are needed to meet public health goals?
•How do we align expectations and requirements from regulators and payers with those of physicians and patients?

› Richard Bergström, Director General, EFPIA (European Federation of Pharmaceutical Industries and Associations)
 
 
9.55am European policy challenges for market access: a way forward?
Andrea RappagliosiBorn in Rome, Andrea Rappagliosi received a law degree from the University of Rome “La Sapienza” and completed a post-graduate Masters at the Istituto Superiore dei Studi Legislativi (ISLE) from which he obtained a “Legislative Consultant Diploma”. ...
more..
•How can we move towards a more collaborative approach between government, payers and industry to prove value?
•How can the new environment ensure that valuable new treatments get to patients?

› Andrea Rappagliosi, Vice President European Government Affairs and Head of Brussels Office, GlaxoSmithKline
 
 
10.20am Speed Networking: Fun high speed networking for making new contacts
 Policy and Payer Updates
 
11.10am Health technology assessment in England and Wales
Meindert BoysenMeindert was trained as a pharmacist in the Netherlands and joined NICE in 2004 as a health technology analyst in London. In 2006 he accepted the post of Associate Director with the responsibility of setting up the new Single Technology Appraisals...
more..
•Overview of the major policy developments that impact technology appraisals
•What is the NICE role in the proposed changes to the drugs approval process
•How is Nice adapting to the new priorities in both industry and in public health?

› Meindert Boysen, Associate Director, NICE
 
 
11.30am Assessing the value of new medicines in Scotland
Anne LeeAnne Lee is a pharmacist and spent her early career in hospital pharmacy, specialising in Medicines Information, working in Edinburgh, Newcastle, and Glasgow. In Newcastle Anne developed a keen interest in the safety of medicines and has edited...
more..
•SMC methodology and experience in the first 10 years
•Current and future challenges

› Anne Lee, Chief Pharmaceutical Advisor, Scottish Medicines Consortium
 
 
11.50am Pharmaceutical uptake and access in the context of UK NHS Reforms
Patrick HopkinsonPatrick is Director of Market Access and External Affairs at Bristol Myers Squibb UK. In his role Patrick leads the key market access functions including Government affairs, Communications, Pricing, HTA and Field Access. He represents BMS in a...
more..
•Preparing to meet the impact of the new system on the way UK pharma companies access and sell in the UK market
•Strategies for communicating to the new payers after healthcare reform

› Patrick Hopkinson, Director Market Access & External Affairs, Bristol-Myers Squibb
 
 
12.10pm The search for value in pharmaceutical pricing
Jim FurnissJim Furniss is Director, Market Access Solutions at Bridgehead International. He has a detailed understanding of pharmaceutical policy, pricing and market access issues throughout Europe and North America and extensive practical experience of...
more..
•Why can’t we leave it to the market?
•What should a pricing scheme deliver?
•How can we assess value?
- Innovation
- Therapeutic benefit
•Is value based pricing possible in practice?
•Value in different indications
•Population based assessment vs. individual patients

› Jim Furniss, Director, Market Access Solutions, Bridgehead International Ltd
 
 
12.40pm Lunch
1.40pm France: Latest developments in pricing and reimbursement policy
Prof Lise RochaixLise Rochaix is full professor in economics, with a Ph.D from York University (UK). She is currently in secondment at the French 'Haute Autorité de Santé' as member of the Board and chair of the technology appraisal committee in charge of economic...
more..
• New developments that reflect the current economic environment and HAS guidance content for a new drug


› Prof Lise Rochaix, Member of the Board, HAS
 
 
2pm Germany: Latest developments in pricing and reimbursement policy
Dr Thomas MuellerThomas Mueller is Medical Doctor and Pharmacist. He completed his studies in Berlin and London, and then worked in the Dermatology Department of the University Hospital Charité Berlin. He completed postgraduate studies in business...
more..
•Short instruction: Drug regulation by the Federal Joint Committee (GBA) in Germany
•First results and experiences with the early benefit assessment of new drugs under the AMNOG-framework
•Latest developments in Germany

› Dr Thomas Mueller, Head of Pharmaceuticals, GBA
 
 
2.20pm IQWiG Perspective
 
› Stefanie Thomas, Drug Assessment, IQWiG
 
 
2.40pm One year after the AMNOG reforms: industry perspective
Markus JahnMarkus had been with Novartis for 10 years in positions in Market Research, Marketing & Sales Analysis and Market Access. He started his career at GfK Healthcare and Siemens Medical in global market research functions. Markus trained as a...
more..
•Pricing roadmap after early benefit assessment - the impact of AMNOG on the price
•Reference price or price negotiation with the national association of SHI funds
•Arbitration board and the impact of European prices
•Reactions of the pharmaceutical industry and first results

› Markus Jahn, Manager, Pricing, Novartis Pharma GmbH
 
 
3pm Afternoon tea
 US Healthcare Reform
 
3.30pm US healthcare policy reform – its impact on market access and patient coverage
Steve PhillipsSteve Phillips is Director, Health Policy and Reimbursement with Johnson & Johnson’ corporate Government Affairs and Policy office. In this role, he provides leadership and guidance in the area of reimbursement to all J&J operating companies. He...
more..
•What are the major changes affecting market access and patient coverage?
•What impacts are expected from what’s in place and what is in store for the future (political and policy scenarios)?

› Steve Phillips, Director, Health Policy & Reimbursement, Johnson & Johnson
 
 
3.50pm CER in evidence based decision making in the US
Jean R. SlutskyMs. Slutsky has directed the Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ) of the U.S. Department of Health and Human Services since June 2003. Prior to Ms. Slutsky’s appointment as director of COE, she...
more..
› Jean R. Slutsky, Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality
 
 
 Canada Focus
 
4.10pm Summary of the past year's PMPRB decisions and a look ahead
Michelle BoudreauAs the senior civil servant executive of the PMPRB, Michelle is responsible for the corporate leadership of the agency, including its strategic direction, voluntary compliance and pricing guidelines, and the management of human and financial...
more..
› Michelle Boudreau, Executive Director, PMPRB
 
 
4.30pm Canada market access overview
Mr. Neil PalmerNeil Palmer is President and Principal Consultant of PDCI Market Access Inc (PDCI) a leading pricing and reimbursement consultancy founded as Palmer D’Angelo Consulting Inc (PDCI) in 1996. In addition to PDCI, Neil has worked with RTI Health...
more..
•Overview of Canadian health care system and pharmaceutical funding
•Price regulation implementation of the new PMPRB guidelines
•CADTH/CDR, pCODR, provincial reimbursement schemes & listing (risk sharing) agreements
•National implications of the Ontario 25% pricing rule for generics
•Implications of international pricing/reimbursement policy reforms
•Outlook for Canadian pricing & reimbursement

› Mr. Neil Palmer, President & Principal Consultant, PDCI Market Access
 
 
5pm Panel discussion

 

8am Registration and coffee
8.30am Opening remarks from the chair
9am Get over it: embrace payer expectations by introducing them early in product development
Dr Raf De WildeRaf De Wilde, PhD, is an expert in global pricing and market access. He recently accepted the role of Associate Vice President for UBC Global Market Access Consulting, after a career of over 30 years in Johnson & Johnson. Dr. De Wilde introduced...
more..
•It does not make sense to start a development program that will not answer the current and to be expected questions from payers
•Key decisions that will make or break market access for a new product are taken very early during development
•Payer expectations also offer opportunities, playing into these
opportunities better than competition can make the difference later in the market
•Special attention will be given to expectations regarding biomarkers, real-world efficacy and comparative effectiveness

› Dr Raf De Wilde, Associate Vice President, Global Market Access Consulting, UBC
 
 
9.30am Case study: Launching and selling a pharmaceutical compound with the payer in mind
Stefan WalzerStefan Walzer has 8 years experience in payer strategy and its implementation and is currently General Manager of Assessment in Medicine (located in Germany). He has been working as a payer consultant for various global pharmaceutical and medical...
more..
•Taking the needs and requests of payers across the world into account when developing a product
•Preparing and executing a communication strategy or payers
•Successfully developing a consistent payer and pricing strategy

› Stefan Walzer, General Manager, AiM Assessment in Medicine
 
 
9.55am Panel discussion: How can payers and industry work together to ensure that innovative and valuable treatments make it to the market?
Dr Raf De WildeRaf De Wilde, PhD, is an expert in global pricing and market access. He recently accepted the role of Associate Vice President for UBC Global Market Access Consulting, after a career of over 30 years in Johnson & Johnson. Dr. De Wilde introduced...
more..Dr Martin van der GraaffDr Graaff spent 4 years in administration form development in Organon, and 7 years in pharmacokinetics and preclinical development at Solvay. He then made the switch from R&D to policy development and moved to Nefarma, the Dutch Association of the...
more..Stefan WalzerStefan Walzer has 8 years experience in payer strategy and its implementation and is currently General Manager of Assessment in Medicine (located in Germany). He has been working as a payer consultant for various global pharmaceutical and medical...
more..
•Where do we agree and where do we differ?
•How big is the gulf and can it be closed?
•Putting patients at the centre of the decision making process

› Dr Raf De Wilde, Associate Vice President, Global Market Access Consulting, UBC
› Dr Martin van der Graaff, Secretary, Reimbursement Committee, CVZ
› Stefan Walzer, General Manager, AiM Assessment in Medicine
 
10.25am Morning coffee
10.55am Learning from best (& worst) practice: pioneering new ways to make Market Access work for healthcare companies
Colin WightColin Wight, Chief Executive, founded GalbraithWight Ltd 15 years ago in January 1997. Dedicated 100% to healthcare, GalbraithWight specialises in global healthcare Consultancy including market access & commercial excellence, and Learning &...
more..
•The good news - what's working well
•The bad news - barriers, hurdles & obstacles to operational success
•Pioneering new ways to make market access work across the company from a global, region & country perspective

› Colin Wight, CEO, GalbraithWight
 
 
11.25am Changing beacons: Navigating the Dutch reimbursement system after 2012 beacons
Dr Martin van der GraaffDr Graaff spent 4 years in administration form development in Organon, and 7 years in pharmacokinetics and preclinical development at Solvay. He then made the switch from R&D to policy development and moved to Nefarma, the Dutch Association of the...
more..
•Conditional reimbursement
•What is an add-on?
•What about results of outcomes research?
•Modernizing the reimbursement system
•Some cases: enthralling or appalling?

› Dr Martin van der Graaff, Secretary, Reimbursement Committee, CVZ
 
 
11.55am Russia
Dr Maria AvxentievaAvxentyeva Maria, Doctor of Medical Sciences, vice-director of the Research Institute of Clinical and Economical Expertise at Russian State Medical University, professor at the Chair of Public Health and Preventive Medicine at Moscow medical academy ...
more..
•Russian health care system: key points
•Introduction of pricing regulation
•Russian reimbursement system – what can be expected?

› Dr Maria Avxentieva, Head of the Research Department of Standardization, Licensing and Accreditation, Moscow Medical Academy
 
 
12.20pm Lunch
1.20pm Market access for orphan drugs
 
•Current reimbursement status for orphan drugs
•What kind of evidence is needed to support claims?
•How can access be improved for orphan treatments?

› Dr Anna Bucsics, Dept Head, Main Association of Austrian Social Security Institutions
 
 
 Asia Focus
 
1.45pm Market access in India
 
•Healthcare trends in the subcontinent
•Review of the purchasing environment
•Impact on pharmaceutical market access

› Rajaram Sankaram, Business Unit Head - Medical Nutrition, Abbott
 
 
2.10pm Taiwan
 
•Healthcare in Taiwan - compulsory national health insurance and National Health Insurance (NHI)
•Rules of pricing and reimbursement and its relationship with HTA assessments
•Future planning for second-generation NHI Act

› Dr Chen-En Tsai, Senior Reseacher, Center for Drug Evaluation, CDE
 
 
2.35pm South Korea
Sang Moo LeeSang Moo Lee MD, PhD is Executive director of Center for New Health Technology Assessment in NECA (National Evidence-based healthcare Collaborating Agency). His background is a clinician, and his major is internal medicine, and his sub-specialty is...
more..
•Overview of the programme to establish universal healthcare insurance coverage and the impact on pharmaceutical market access
•Dealing with uncertainty
•Conclusions

› Sang Moo Lee, Executive Director, Division of new Health Technology Assessment, National Evidence-based Healthcare Collaborating Agency
 
 
3pm Panel discussion: Overcoming the barriers to entry in Asia
Sang Moo LeeSang Moo Lee MD, PhD is Executive director of Center for New Health Technology Assessment in NECA (National Evidence-based healthcare Collaborating Agency). His background is a clinician, and his major is internal medicine, and his sub-specialty is...
more..
•What are the opportunities for the pharmaceutical industry?
•How are we working with payers and governments?
•What improvements are needed to ensure market access?

› Rajaram Sankaram, Business Unit Head - Medical Nutrition, Abbott
› Dr Chen-En Tsai, Senior Reseacher, Center for Drug Evaluation, CDE
› Sang Moo Lee, Executive Director, Division of new Health Technology Assessment, National Evidence-based Healthcare Collaborating Agency
 
3.30pm Afternoon tea and end of conference

 
 
Organized by: Health Network Communications
Invited Speakers:

Dr Sang Moo Lee, Executive Director, NECA South Korea

Meindert Boysen, Programme Director, NICE UK

Thomas Mueller, Head of Pharmaceuticals, G-BA Germany

Prof Lise Rochaix, Member of the board, HAS France

Stefanie Thomas, Drug Assessment, IQWiG Germany

+ Many more

 
Deadline for Abstracts: 25/01/20125
 
Registration:

Book before 11 Feb to register for only £1450 for the 2 day conference.

Call Sabrina on +44 (0) 207 608 7055

E-mail: kbarden@healthnetworkcommunications.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.